CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
CCTG will be holding the next CRA Lunch and Learn on Wednesday June 11th, 2025, at 12 pm ET. Session 5 will cover the topic of Understanding the Centre Performance Index (CPI)
The 2025 CCTG Spring Meeting of Participants wrapped up with a record 941 members attending. This dynamic gathering helped shape our future research agenda and celebrated many achievements across our network.
The SRC8 clinical trial is now open for enrollment and will investigate whether a combination of immunotherapy and chemotherapy is more effective than chemotherapy alone for adults with advanced sarcoma, specifically undifferentiated pleomorphic or poorly differentiated sarcoma subtypes.
The PR.19 Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer has successfully reached the sample size of 335 participants and is now closed to further accrual.
Online preregistration closes April 10Preregistering online through your e-invitation will ensure a faster on-site registration process as you will have already completed the Undertaking of Confidentiality, and your name tag will be ready for pick-up.
